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Remember the Modiﬁable Bleeding Risk Factors*Gregory Y.H. Lip, MD,yz Deirdre A. Lane, PHDySEE PAGE 2271A pproximately 5 years ago, when deciding onoral anticoagulation (OAC) for stroke preven-tion in atrial ﬁbrillation (AF), we did not have
a choice; only the vitamin K antagonists (VKA; e.g.,
warfarin) were available. In 2015, in addition to
VKAs, we currently have 4 licensed non-VKA oral
anticoagulants (NOACs), and therefore have the
opportunity to ﬁt the most appropriate drug to the
patient’s risk proﬁle, and vice versa.
OAC confers a risk of bleeding, including gastro-
intestinal (GI) bleeding, as do antiplatelet drugs. In
their respective randomized trials, an excess of GI
bleeding compared with warfarin was seen with
dabigatran 150 mg bid, rivaroxaban, and edoxaban
60 mg (1). No excess GI bleeding was seen with
dabigatran 110 mg or apixaban 5 mg bid. Overall, a
lower rate of major bleeding was seen with dabigatran
110 mg bid, apixaban, and edoxaban when compared
with warfarin. The lower risk of bleeding has been
conﬁrmed by indirect comparisons of the NOACs
against each other (2).
In this issue of the Journal, Sherwood et al. (3)
present an ancillary analysis from ROCKET-AF
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Fibrillation), which evaluated GI bleeding in the
on-treatment population. There were signiﬁcantly
more major or nonmajor clinically relevant GI
bleeding events on rivaroxaban (3.61 vs. 2.60 events/
100 patient-years; hazard ratio [HR]: 1.42; 95%
CI: 1.22 to 1.66), compared with warfarin-treatedpatients. This increased risk of both major and clini-
cally relevant nonmajor GI bleeding among patients
taking rivaroxaban persisted in multivariable ana-
lyses. However, severe GI bleeding rates and location
were similar between treatment arms (48% upper GI
tract, 23% lower GI tract, and 29% rectal), with few
fatal GI bleeding events.
Of note, the mean CHADS2 (congestive heart failure,
hypertension, age $75 years, diabetes mellitus,
prior stroke or TIA), CHA2DS2-VASc (congestive
heart failure, hypertension, age $75 years, diabetes
mellitus, prior stroke or TIA or thromboembolism,
vascular disease, age 65-74 years, sex category
[female]), and HAS-BLED (uncontrolled systolic
hypertension, abnormal renal and liver function,
stroke, bleeding, labile international normalized
ratios [INRs], elderly [>65 years], concomitant anti-
platelets, nonsteroidal anti-inﬂammatory drugs
[NSAIDs], or excess alcohol) scores were similar in
patients with and without GI bleeding. Stroke risk and
bleeding risks track each other, and bleeding rates can
rise with increasing CHADS2 and CHA2DS2-VASc
scores; however, the HAS-BLED score outperformed
the 2 stroke risk scores for predicting clinically rele-
vant bleeding (4,5). Attempts to derive a composite
stroke and bleeding risk score offered additional
complexity but minimal improvement in predictive
value over the individual CHA2DS2-VASc or HAS-BLED
scores (6,7). Thus, stroke risk should be assessed using
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2283a speciﬁc stroke risk score, that is, the CHA2DS2-VASc;
and bleeding risk should be assessed using a speciﬁc
bleeding risk score, HAS-BLED.
Clinical factors associated with GI bleeding in the
ROCKET-AF cohort were anemia at baseline, prior
history of GI bleeding, rivaroxaban (vs. warfarin use),
and chronic aspirin or NSAIDs use. There was also a
higher prevalence of renal impairment, diabetes, and
hypertension among the patients with GI bleeding.
Interestingly, many of these clinical factors are
incorporated into the HAS-BLED score (8). The latter
was proposed as a simple practical score to identify
patients potentially at risk of bleeding for more vigi-
lant follow-up and review, and to address the
potentially reversible bleeding risk factors, that is,
uncontrolled hypertension (the H in HAS-BLED),
labile INRs (only applies if the patient is taking VKA,
the L criterion), concomitant use of aspirin or NSAIDs
with anticoagulation and/or alcohol excess (the D
criterion in HAS-BLED), and so on (9).
The emphasis on correcting the potentially re-
versible bleeding risk factors is emphasized in
guidelines from the European Society of Cardiology
and the National Institute for Health and Care
Excellence (10). Also, a high HAS-BLED score is not an
excuse to withhold OAC. Indeed, Sherwood et al. (3)emphasize the need for minimizing modiﬁable risk
factors for GI bleeding in patients on OAC, which is a
very sensible approach.
For example, a 55-year-old AF patient with poorly
controlled hypertension, excessive alcohol intake,
and taking warfarin with a time in therapeutic range
(TTR) of 50% (i.e., poor anticoagulation control)
would have a HAS-BLED score of 3 (i.e., high risk of
bleeding). Consequently, the responsible physician
would address that patient’s risk factors by con-
trolling blood pressure, reducing alcohol intake,
and directing better efforts to improve the TTR or
consider switching the patient to a NOAC. Thus,
other bleeding risk scores that unduly simplify
things by not incorporating parameters such as
labile INRs (in a patient taking warfarin) or uncon-
trolled hypertension may erroneously categorize
a patient as being at low risk, and potentially
correctable bleeding risk factors may not be
addressed.
Interestingly, some geographical variation was
evident in GI bleeding. Quality of anticoagulation
control in the warfarin arm, as reﬂected by the time in
therapeutic range, was higher in North America
(65.5%) compared with the rest of the world (55.7%).
Patients in North America receiving rivaroxaban had
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compared with warfarin. In this region, rivaroxaban
was being compared with best managedwarfarin (with
a TTR of 65.5%) and bleeding onwarfarin is very closely
related to TTR (11,12). Hence, the 1.89-fold excess GI
bleeding risk on rivaroxaban is perhaps unsurprising.
For the rest of the world, there was a 21% increase
in GI bleeding risk on rivaroxaban compared with
warfarin. In the rest of the world, the TTR was 55.7%,
reﬂecting less optimal anticoagulation control on
warfarin; despite this, there was still a 1.21-fold
excess of GI bleeding. Inadequate time in therapeu-
tic range is a continuing problem, and may be one
explanation for the higher rates of thromboembolism
and serious bleeding among Asians compared with
non-Asians (13). Poor anticoagulation control (i.e.,
labile INRs) translates into an excess of thromboem-
bolism, mortality, and bleeding (14).
Notwithstanding the issues with GI bleeding, we
should not forget that, overall, the NOACs have
changed the landscape for stroke prevention in AF.
These drugs offer relative efﬁcacy, safety, and conve-
nience compared with the VKAs and, given theavailability of various NOAC drugs as well as VKAs
(assuming good TTR), we are nowadays spoilt for
choice, and have the opportunity to ﬁt the drug to
various patient characteristics (Figure 1). Even a single
additional stroke risk factor confers a real increased
risk of stroke and mortality that is signiﬁcantly
reduced by OAC (and with a positive net clinical
beneﬁt as well) (15,16). Thus, rather than a categorical
approach to stroke risk stratiﬁcation and treatment
decisions, the initial step should be to identify those at
“low risk” (i.e., CHA2DS2-VASc 0 in men, 1 in women)
who do not need any antithrombotic therapy (9). The
second step should then be to offer effective stroke
prevention, which is OAC, to those AF patients with$1
additional stroke risk factors. Only such a proactive
approach will help to reduce the burden of stroke
associated with this common arrhythmia.
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